CMV Chemotherapy for Advanced Transitional Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 1992 Sep 1

PMID 1520591

Citations 2

Authors

G M Jeffery

G M Mead

Affiliations

Soon will be listed here.

Abstract

Between May 1986 and September 1990 a total of 43 patients with metastatic transitional cell carcinoma (TCC) of the urinary tract have been treated at our institution with combination chemotherapy (CMV) consisting of cisplatin 100 mg m-2 i.v. day 2; methotrexate 30 mg m-2 i.v. days 1.8; and vinblastine 4 mg m-2 i.v. days 1.8. Chemotherapy was recycled on day 22 and continued for a maximum of six cycles in responding patients. Of 33 patients with measurable disease 8 (24%) achieved a complete remission (CR). The median survival for patients achieving a CR was 13 months (range 5-29+) whilst the median survival for all 43 patients was 7 months (range 1-29+). Only three patients are still alive--two are disease free. More effective and/or less toxic chemotherapy regimens are needed for the treatment of patients with metastatic TCC.

Citing Articles

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced....

Mead G, Russell M, Clark P, Harland S, Harper P, Cowan R Br J Cancer. 1998; 78(8):1067-75.

PMID: 9792152 PMC: 2063167. DOI: 10.1038/bjc.1998.629.

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.

Fossa S, Sternberg C, Scher H, Theodore C, Mead B, Dearnaley D Br J Cancer. 1996; 74(10):1655-9.

PMID: 8932351 PMC: 2074866. DOI: 10.1038/bjc.1996.605.

References

Troner M, Birch R, Omura G, Williams S . Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol. 1987; 137(4):660-2. DOI: 10.1016/s0022-5347(17)44167-x. View

Sternberg C, Yagoda A, Scher H, Watson R, Herr H, Morse M . M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988; 139(3):461-9. DOI: 10.1016/s0022-5347(17)42494-3. View

Yagoda A . Chemotherapy of metastatic bladder cancer. Cancer. 1980; 45(7 Suppl):1879-88. View

Babaian R, Johnson D, Llamas L, Ayala A . Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980; 16(2):142-4. DOI: 10.1016/0090-4295(80)90067-9. View

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

HILLCOAT B, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R . A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol. 1989; 7(6):706-9. DOI: 10.1200/JCO.1989.7.6.706. View

Tannock I, Gospodarowicz M, Connolly J, Jewett M . M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989; 142(2 Pt 1):289-92. DOI: 10.1016/s0022-5347(17)38733-5. View

Potter M, Hatch K, Potter M, SHINGLETON H, Baker V . Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer. 1989; 63(7):1283-6. DOI: 10.1002/1097-0142(19890401)63:7<1283::aid-cncr2820630709>3.0.co;2-u. View

Sternberg C, Yagoda A, Scher H, Watson R, Ahmed T, Weiselberg L . Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985; 133(3):403-7. DOI: 10.1016/s0022-5347(17)48996-8. View

10.

Soloway M, Einstein A, Corder M, Bonney W, Prout Jr G, Coombs J . A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer. 1983; 52(5):767-72. DOI: 10.1002/1097-0142(19830901)52:5<767::aid-cncr2820520502>3.0.co;2-p. View

11.

Logothetis C, Dexeus F, Sella A, Amato R, Kilbourn R, Finn L . Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1990; 82(8):667-72. DOI: 10.1093/jnci/82.8.667. View

12.

Logothetis C, Dexeus F, Finn L, Sella A, Amato R, Ayala A . A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990; 8(6):1050-5. DOI: 10.1200/JCO.1990.8.6.1050. View

13.

Scher H . Should single agents be standard therapy for urothelial tract tumors?. J Clin Oncol. 1989; 7(6):694-7. DOI: 10.1200/JCO.1989.7.6.694. View

14.

Sternberg C, Yagoda A, Scher H, Watson R, Geller N, Herr H . Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989; 64(12):2448-58. DOI: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. View

15.

Harker W, Meyers F, Freiha F, Palmer J, Shortliffe L, Hannigan J . Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985; 3(11):1463-70. DOI: 10.1200/JCO.1985.3.11.1463. View